Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.
Wang Y, Deng B.
Cancer Metastasis Rev. 2023 Sep;42(3):629-652. doi: 10.1007/s10555-023-10084-4. Epub 2023 Feb 2.
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis.
Lev S.
Biochem Soc Trans. 2020 Apr 29;48(2):657-665. doi: 10.1042/BST20191055.
Targeted Therapy and Personalized Medicine.
Saeed RF, Awan UA, Saeed S, Mumtaz S, Akhtar N, Aslam S.
Cancer Treat Res. 2023;185:177-205. doi: 10.1007/978-3-031-27156-4_10.
Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review.
Nappi F.
Int J Mol Sci. 2024 Mar 24;25(7):3630. doi: 10.3390/ijms25073630.
Cancer treatment therapies: traditional to modern approaches to combat cancers.
Kaur R, Bhardwaj A, Gupta S.
Mol Biol Rep. 2023 Nov;50(11):9663-9676. doi: 10.1007/s11033-023-08809-3. Epub 2023 Oct 12.
RNA-Targeted Therapeutics.
Crooke ST, Witztum JL, Bennett CF, Baker BF.
Cell Metab. 2018 Apr 3;27(4):714-739. doi: 10.1016/j.cmet.2018.03.004.
Targeting AKT for cancer therapy.
Shariati M, Meric-Bernstam F.
Expert Opin Investig Drugs. 2019 Nov;28(11):977-988. doi: 10.1080/13543784.2019.1676726. Epub 2019 Oct 12.
Towards targeted cancer therapy: Aptamer or oncolytic virus?
Tan KX, Danquah MK, Sidhu A, Ongkudon CM, Lau SY.
Eur J Pharm Sci. 2017 Jan 1;96:8-19. doi: 10.1016/j.ejps.2016.08.061. Epub 2016 Sep 1.
Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP.
BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674.
Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.
Lazaro T, Brastianos PK.
CNS Oncol. 2017 Apr;6(2):139-151. doi: 10.2217/cns-2016-0038.
